Scarica l'app Stockscreener
0.447
6.43%
0.027
Dopo l'orario di chiusura:
.45
0.003
+0.67%
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expertICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - gosanangelo.com
Medicus Pharma stock swings after skin cancer treatment results - MSN
Medicus Pharma on Bloomberg World - Bluffton Today
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Singapore
Medicus Pharma clarifies Phase 2 skin cancer study results By Investing.com - Investing.com South Africa
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike - Stock Titan
CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant - Stock Titan
[Form 4] Medicus Pharma Ltd. Insider Trading Activity - Stock Titan
Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares - Stock Titan
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan
Medicus Pharma (MDCX) grants director 25K stock options at $0.50 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer receives 25,000 stock options grant - Stock Titan
Medicus Pharma (MDCX) grants CFO 100,000 stock options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike - Stock Titan
Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike - Stock Titan
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data - Yahoo Finance
Medicus Pharma Ltd clarifies positive Skinject phase 2 dataset - MarketScreener
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset - The Manila Times
Medicus Pharma clarifies Phase 2 skin cancer study results - Investing.com
Skin cancer study points to stronger results at higher SkinJect dose - Stock Titan
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow | Medicus Pharma Ltd - Stock Titan
MDCX Stock Price, Quote & Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Ideas Watch: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackQuarterly Portfolio Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Small cap wrap: Namibia Critical Metals, Medicus Pharma, Greatland Resources... - Proactive financial news
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate - tipranks.com
Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2 - tipranks.com
D. Boral Capital cuts Medicus Pharma stock price target on dilution concerns - ca.investing.com
Medicus Pharma highlights independent support for Phase 2 SkinJect results - Yahoo! Finance Canada
Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response Rate - MarketScreener
Medicus Pharma reports Kol validation of Skinject phase 2 data of 80% overall response rate - MarketScreener
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate - Caledonian Record
[EFFECT] Medicus Pharma Ltd. SEC Filing - Stock Titan
Bull Bear: Is Medicus Pharma Ltd Equity Warrant stock forming a cup and handleMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Free cash flow per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026 - openPR.com
Medicus Pharma reports 80% response rate in skin cancer study By Investing.com - Investing.com South Africa
Medicus Pharma to host business update call featuring clinical investigator - MSN
Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan - TipRanks
Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026 - Yahoo Finance
Medicus Pharma reports 80% response rate in skin cancer study - Investing.com
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan - The Manila Times
0.81%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):